A new bilingual telehealth clinic, Sol y Vida, launched nationwide today to address significant disparities in access to advanced metabolic care, including GLP-1 medications, among Latino patients. The clinic, founded by Edgar Estrada, offers medical weight loss and metabolic care from licensed clinicians in both English and Spanish across all 50 states. The launch coincides with the start of Hispanic Heritage Month on September 15.
The need for such a service is underscored by stark statistics. A 2024 national cohort study found that Hispanic patients are 47% less likely than White patients to be prescribed the newest GLP-1 medications. Furthermore, the National Hispanic Medical Association estimates that just 2% of eligible Latino patients access anti-obesity medications. Language barriers compound the problem: according to HHS, 68% of Hispanics and Latinos speak a language other than English at home.
Sol y Vida aims to bridge this gap by providing culturally and linguistically competent care. "We created Sol y Vida to provide another option — one where patients can communicate comfortably, understand their care and have meaningful conversations with licensed healthcare professionals in the language they prefer," said founder Edgar Estrada. The clinic's services are available in all 50 states, with care beginning with a free 20-minute first consultation and no commitment. Licensed clinicians determine whether treatment is medically appropriate and prescribe accordingly. Programs include compounded semaglutide, dispensed by licensed compounding pharmacies.
The launch comes amid heightened regulatory scrutiny of telehealth marketing of compounded GLP-1 medications. Since late 2025, the FDA has sent three waves of warning letters over such marketing. Sol y Vida distinguishes itself by taking a compliance-focused approach: it is LegitScript-certified (verifiable at legitscript.com), publishes its program prices, and its press kit lists the claims it will not make. This philosophy is outlined in a blog post titled "recetado, no comprado" (prescribed, not purchased) at solyvidaclinic.com/blog/por-que-recetado-no-comprado.
The clinic emphasizes transparency regarding compounded medications. It notes that compounded medications are not FDA-approved, meaning the FDA does not review them for safety, effectiveness, or quality. Individual results may vary. For more information, visit solyvidaclinic.com.
For a healthcare industry increasingly focused on health equity, Sol y Vida's launch represents a targeted effort to reach a demographic that has been underserved in the rapidly growing GLP-1 market. By offering bilingual services and a compliance-forward model, the clinic may help set a standard for inclusive telehealth care. As the demand for metabolic treatments continues to rise, addressing language and access barriers could be crucial in ensuring that all patients, regardless of background, can benefit from these advances.
